X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 91 filers reported holding X4 PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,718 | -94.8% | 1,576 | -90.8% | 0.00% | – |
| Q2 2023 | $33,236 | +553833.3% | 17,132 | +285433.3% | 0.00% | – |
| Q1 2023 | $6 | -100.0% | 6 | -99.9% | 0.00% | – |
| Q3 2022 | $17,000 | -86.0% | 10,000 | -81.1% | 0.00% | – |
| Q4 2021 | $121,000 | -85.0% | 53,031 | -65.3% | 0.00% | – |
| Q3 2021 | $808,000 | -41.5% | 152,831 | -28.1% | 0.00% | – |
| Q2 2021 | $1,382,000 | -24.5% | 212,620 | 0.0% | 0.00% | – |
| Q1 2021 | $1,831,000 | +33.9% | 212,620 | 0.0% | 0.00% | – |
| Q4 2020 | $1,367,000 | -9.0% | 212,620 | -4.2% | 0.00% | – |
| Q3 2020 | $1,502,000 | -76.9% | 221,912 | -68.2% | 0.00% | -100.0% |
| Q2 2020 | $6,503,000 | -6.8% | 697,800 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $6,978,000 | -27.5% | 697,800 | -22.5% | 0.00% | 0.0% |
| Q4 2019 | $9,630,000 | -15.8% | 900,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $11,439,000 | -15.3% | 900,000 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $13,500,000 | – | 900,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,682,000 | 3.48% |
| Sio Capital Management, LLC | 804,597 | $6,928,000 | 1.41% |
| Bain Capital Life Sciences Investors, LLC | 2,119,540 | $18,249,000 | 1.03% |
| SV Health Investors, LLC | 311,490 | $2,682,000 | 1.00% |
| Monashee Investment Management LLC | 574,712 | $4,948,000 | 0.76% |
| Ikarian Capital, LLC | 2,614,988 | $22,515,000 | 0.76% |
| Abingworth LLP | 229,885 | $1,956,000 | 0.68% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,884,000 | 0.67% |
| BVF INC/IL | 1,091,579 | $9,398,000 | 0.35% |
| Endurant Capital Management LP | 151,996 | $1,309,000 | 0.34% |